Blog Posts

Raffaele Colombo: Sacituzumab Tirumotecan Versus Docetaxel in EGFR-Mutated Advanced NSCLC

Raffaele Colombo/LinkedIn

Jun 12, 2025, 10:54

Raffaele Colombo: Sacituzumab Tirumotecan Versus Docetaxel in EGFR-Mutated Advanced NSCLC

Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, posted on X:

“OptiTROP-Lung03 published on The BMJ: sacituzumab tirumotecan (sac-TMT) versus docetaxel for previously treated EGFR-mutated advanced NSCLC.

sac-TMT vs docetaxel
ORR: 45% vs 16%
PFS: 6.9 vs 2.8 months
OS: NR, HR=0.49

(data also presented at ASCO25).”

Title: Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial

Authors: Wenfeng Fang, Xingya Li, Qiming Wang, Xiangjiao Meng, Wei Zheng, Longhua Sun, Wenxiu Yao, Wu Zhuang, Yun Fan, Minglei Zhuo, Yongzhong Luo, Zhiye Zhang, Xia Song, Runxiang Yang, Jiacheng Yang, Xiaoping Jin, Yina Diao, Junyou Ge, Li Zhang

Read The Full Article at The BMJ.

Raffaele Colombo: Sacituzumab Tirumotecan Versus Docetaxel in EGFR-Mutated Advanced NSCLC

More posts featuring Raffaele Colombo.

ASCO25 cancer Jiacheng Yang Junyou Ge Li Zhang Longhua Sun Minglei Zhuo NSCLC OncoDaily Oncology Qiming Wang Raffaele Colombo Runxiang Yang The BMJ Wei Zheng Wenfeng Fang Wenxiu Yao Wu Zhuang Xia Song Xiangjiao Meng Xiaoping Jin Xingya Li Yina Diao Yongzhong Luo Yun Fan Zhiye Zhang

Patrick Soon-Shiong: 30 Years and $3B Toward a Universal Cancer Fighter

Vinay Prasad Rejoins FDA Days After Exit

New Paper Alert: Safety and Outcomes of T-DXd Retreatment After Grade 1 ILD Recovery

FDA Accepts NDA for Vepdegestrant in ESR1-Mutant ER+/HER2- Advanced Breast Cancer

Hubert Caron Retires from Roche-Genentech